Lipocine (NASDAQ:LPCN) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN) in a research report report published on Thursday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners began coverage on Lipocine in a research note on Tuesday, September 24th. They set a “buy” rating and a $10.00 target price for the company.

Lipocine Trading Down 1.1 %

Shares of NASDAQ:LPCN opened at $5.23 on Thursday. The company has a 50 day moving average of $5.02 and a 200-day moving average of $5.17. The firm has a market cap of $27.97 million, a P/E ratio of -6.88 and a beta of 1.23. Lipocine has a twelve month low of $2.82 and a twelve month high of $11.79.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter. Equities research analysts forecast that Lipocine will post -0.78 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Lipocine stock. Renaissance Technologies LLC lifted its stake in Lipocine Inc. (NASDAQ:LPCN) by 21.8% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 25,697 shares of the specialty pharmaceutical company’s stock after purchasing an additional 4,600 shares during the quarter. Renaissance Technologies LLC owned 0.48% of Lipocine worth $212,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.